Biomarin Pharmaceutical (BMRN) Depreciation & Amortization (CF) (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $16.4 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 25.64% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.9 million (down 18.92% YoY) and the FY2025 annual result came in at $79.6 million, down 17.49% from the prior year.
• Depreciation & Amortization (CF) slipped to $16.4 million in Q1 2026, from $20.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $27.4 million in Q1 2024 to a low of $16.4 million in Q1 2026.
• A 5-year average of $23.5 million and a median of $24.8 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) advanced 9.4% — and 2025, when it fell 29.85%.
• Tracing BMRN's Depreciation & Amortization (CF) over 5 years: stood at $24.6 million in 2022, then gained by 9.4% to $26.9 million in 2023, then decreased by 12.11% to $23.6 million in 2024, then declined by 13.42% to $20.4 million in 2025, then fell by 19.7% to $16.4 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $16.4 million (Q1 2026), $20.4 million (Q4 2025), and $18.5 million (Q3 2025), per Business Quant data.